Hazard Information | Back Directory | [Uses]
Amubarvimab (BRII-196) is a human IgG1 mAb that bind to non-competing epitopes on the receptor binding domain (RBD) of spike protein, with a KD of 5.88 nM. Amubarvimab can effectively neutralize SARS-CoV-2 variants[1][2]. | [in vivo]
Amubarvimab (10-50 mg/kg; i.p.) in combination with romlusevimab significantly decreases viral load in the lungs, and reduces lung pathology in a Syrian golden hamster model of SARS-CoV-2 infection[1]. | [References]
[1] Ji Y, et, al. Preclinical characterization of amubarvimab and romlusevimab, a pair of non-competing neutralizing monoclonal antibody cocktail, against SARS-CoV-2. Front Immunol. 2022 Sep 14;13:980435. DOI:10.3389/fimmu.2022.980435 [2] Hoy SM. Amubarvimab/Romlusevimab: First Approval. Drug. 2022 Aug;82(12):1327-1331. DOI:10.1007/s40265-022-01759-3 |
|
Company Name: |
Biolab Reagents
|
Tel: |
18108604356 18108604356 |
Website: |
www.biolabreagent.com/ |
Company Name: |
Cell Sciences
|
Tel: |
9785721070 |
Website: |
www.cellsciences.com |
|